Adalimumab biosimilar (Alvotech)

阿达木单抗生物类似药 (Alvotech)

Report date: 2024/02/27 09:20:59

Base Information

Drug NameAdalimumab biosimilar (Alvotech)
Drug Alias NameRecombinant human anti-tumour necrosis factor alpha (TNF-α) monoclonal antibody (Alvotech)重组抗肿瘤坏死因子-α全人源单抗 (Alvotech)阿达木单抗生物仿制药 (Alvotech)Adalimumab biosimilar（Mabxience）重组抗TNFa全人单抗 (Alvotech) +[12] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsImmunosuppressants
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisInflammation +[13] 
Global Approved IndicationsPlaque psoriasisPsoriasisUveitis +[11] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2021/11/12
Country/TerritoryUnited StatesUkrainePoland +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlvotech hf
China Registration ClassN/A

Develop Information

Active CompaniesBioventure FZ-LLCAlvotech USA IncChangchun High And New Technology Industries (Group) Inc +[6] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisNon-radiographic axial spondyloarthritisInflammation +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A